Last Updated: May 14, 2026

Patent: 7,977,464


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,977,464
Title:Antibody molecules specific to human tumour necrosis factor alpha
Abstract:There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.
Inventor(s):Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
Assignee: UCB SA , Celltech R&D Ltd
Application Number:US12/141,667
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 7,977,464: Claims Dissection and US Landscape Impact

What does US 7,977,464 claim at the core?

US 7,977,464 is a US patent with an issuance date of July 12, 2011. The patent’s claim set and full specification are required to produce a true claim-chart level analysis (claim scope, dependency structure, and legal vulnerabilities). That content is not provided in the prompt, and the document text is not available within this interface.

Because the patent’s independent claim language and material dependent limitations are not present here, a complete and accurate claim-by-claim analysis cannot be produced.

What is the prosecution and validity posture for US 7,977,464?

A validity and prosecution-landscape assessment requires at least one of the following: (1) file history (e.g., IDS, office actions, amendments), (2) known litigation outcomes (district court or ITC), or (3) identified asserted grounds (112/101/103/102) tied to specific prior art.

The prompt does not include any file history, litigation docket, reexamination, or asserted prior art. Without that, a critical validity posture cannot be completed without fabricating facts.

How crowded is the US prior-art landscape around the asserted subject matter?

A meaningful “crowding” analysis requires identifying the technological subject matter and matching it to relevant prior art families and patent citations. That mapping depends on the patent’s actual claim terms.

Since the claim terms and technical area are not provided, there is no basis to determine:

  • which US applications/patents are likely closest,
  • what publication years bracket the filing date,
  • how many continuations or enforcement-adjacent filings exist,
  • and whether the closest prior art targets the same claim elements.

Which claim elements are most likely to drive infringement and non-infringement?

This determination is claim-language dependent and requires at minimum:

  • independent claim element list,
  • dependent claim limitations that narrow or define key features,
  • and any explicit definitions or preferred embodiments that control claim construction.

No claim text was provided. Without it, any element-level ranking would be speculative.

What are the most likely design-around paths in the US market?

Design-around strategies hinge on what the patent actually requires (materials, functional steps, system architecture, performance parameters, or structural constraints). With no claim text, there is no reliable way to derive design-arounds or assess their likelihood.

What does the US enforcement landscape look like?

Enforcement analysis requires at least one of:

  • assignment records tied to enforcement entities,
  • licensing behavior,
  • known suits involving the same claims,
  • or citation-based family patterns indicating enforcement intent.

The prompt provides none of these.

Claim chart and claim construction readiness

A business-ready claim construction plan must include:

  • independent claim scope,
  • term definitions and potential broadest reasonable interpretation issues,
  • how dependent claims limit the independent claims,
  • and which prior art categories attack each limitation.

No claim language is present; therefore a claim chart cannot be generated.


Key Takeaways

  • A comprehensive, critical analysis of US Patent 7,977,464 requires the actual claim set and specification (claim language drives scope, vulnerability, prior-art mapping, and design-around strategy).
  • The prompt contains no claim text, file history, litigation record, or prior-art citation list, so a complete and accurate patent-landscape analysis cannot be produced without making unsupported assertions.

FAQs

1) Can I get a claim-by-claim analysis without the claim text?

No. Claim scope, dependencies, and legal vulnerability depend on the exact wording of independent and dependent claims.

2) Does the patent number alone identify the technology well enough to assess prior art?

No. US patent numbers are identifiers, not substitutes for the claim limitations that determine novelty and obviousness.

3) What inputs are required for a validity landscape map (102/103/112/101)?

File history and/or the patent’s cited prior art, plus the claim terms the grounds apply to.

4) How do design-around options get derived?

From the specific limitations that are required by the claims and the commercially available alternative architectures, materials, or process steps that avoid those limitations.

5) What is the fastest path to an investable landscape read?

A structured claim and prior-art matrix built from the patent text and the closest cited references, then validated against enforcement or litigation signals.


References

[1] United States Patent US 7,977,464 (bibliographic record).

More… ↓

⤷  Start Trial

Details for Patent 7,977,464

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ucb, Inc. CIMZIA certolizumab pegol For Injection 125160 April 22, 2008 7,977,464 2028-06-18
Ucb, Inc. CIMZIA certolizumab pegol Injection 125160 March 28, 2019 7,977,464 2028-06-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.